PMID- 28529723 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20191120 IS - 2046-1402 (Print) IS - 2046-1402 (Electronic) IS - 2046-1402 (Linking) VI - 6 DP - 2017 TI - Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation. PG - 617 LID - 10.12688/f1000research.10990.1 [doi] LID - 617 AB - Graft-versus-host disease (GVHD) remains a significant potentially life-threatening complication of allogeneic hematopoietic cell transplantation (HCT). Since the discovery of the human leukocyte antigen (HLA) system over 50 years ago, significant advances have clarified the nature of HLA variation between transplant recipients and donors as a chief etiology of GVHD. New information on coding and non-coding gene variation and GVHD risk provides clinicians with options to consider selected mismatched donors when matched donors are not available. These advances have increased the availability of unrelated donors for patients in need of a transplant and have lowered the overall morbidity and mortality of HCT. FAU - Petersdorf, Effie W AU - Petersdorf EW AD - Fred Hutchinson Cancer Research Center, Seattle, WA, USA. LA - eng GR - U01 AI069197/AI/NIAID NIH HHS/United States PT - Journal Article PT - Review DEP - 20170503 PL - England TA - F1000Res JT - F1000Research JID - 101594320 PMC - PMC5419254 OTO - NOTNLM OT - HLA expression OT - MHC OT - haplotype OT - hematopoietic cell transplantation OT - permissible HLA mismatch COIS- Competing interests: The author declares that she has no competing interests.No competing interests were disclosed.No competing interests were disclosed. EDAT- 2017/05/23 06:00 MHDA- 2017/05/23 06:01 PMCR- 2017/05/03 CRDT- 2017/05/23 06:00 PHST- 2017/04/25 00:00 [accepted] PHST- 2017/05/23 06:00 [entrez] PHST- 2017/05/23 06:00 [pubmed] PHST- 2017/05/23 06:01 [medline] PHST- 2017/05/03 00:00 [pmc-release] AID - 10.12688/f1000research.10990.1 [doi] PST - epublish SO - F1000Res. 2017 May 3;6:617. doi: 10.12688/f1000research.10990.1. eCollection 2017.